Milos Opravil

Summary

Affiliation: University Hospital
Country: Switzerland

Publications

  1. ncbi request reprint Effect of baseline CD4 cell count on the efficacy and safety of peginterferon Alfa-2a (40KD) plus ribavirin in patients with HIV/hepatitis C virus coinfection
    Milos Opravil
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland
    J Acquir Immune Defic Syndr 47:36-49. 2008
  2. doi request reprint CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy
    Nina Khanna
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital, Basel, Switzerland
    Clin Infect Dis 47:1093-101. 2008
  3. pmc Impact of previous virological treatment failures and adherence on the outcome of antiretroviral therapy in 2007
    Marie Ballif
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
    PLoS ONE 4:e8275. 2009
  4. ncbi request reprint Eligibility for and outcome of hepatitis C treatment of HIV-coinfected individuals in clinical practice: the Swiss HIV cohort study
    Annelies S Zinkernagel
    Division of Infectious Diseases and Hospital Epidemiology, Department of Internal Medicine, University Hospital, Zurich, Switzerland
    Antivir Ther 11:131-42. 2006
  5. ncbi request reprint Treatment initiation with zidovudine-containing potent antiretroviral therapy impairs CD4 cell count recovery but not clinical efficacy
    Angela C Huttner
    University Hospital of Zurich, Zurich, Switzerland
    AIDS 21:939-46. 2007
  6. ncbi request reprint Equal amounts of intracellular and virion-enclosed hepatitis C virus RNA are associated with peripheral-blood mononuclear cells in vivo
    Philipp Kaiser
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, 8032 Zurich, Switzerland
    J Infect Dis 194:1713-23. 2006
  7. ncbi request reprint Optimized virus disruption improves detection of HIV-1 p24 in particles and uncovers a p24 reactivity in patients with undetectable HIV-1 RNA under long-term HAART
    Jorg Schupbach
    Swiss National Center for Retroviruses, University of Zurich, Zurich, Switzerland
    J Med Virol 78:1003-10. 2006
  8. ncbi request reprint Attenuated and nonproductive viral transcription in the lymphatic tissue of HIV-1-infected patients receiving potent antiretroviral therapy
    Marek Fischer
    Division of Infectious Diseases and Hospital Epidemiology, Department of Medicine, University Hospital Zurich, Zurich, Switzerland
    J Infect Dis 189:273-85. 2004
  9. doi request reprint Higher CNS penetration-effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid
    Alexia Cusini
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
    J Acquir Immune Defic Syndr 62:28-35. 2013
  10. ncbi request reprint Impact of genotypic resistance testing on selection of salvage regimen in clinical practice
    Stefan Haupts
    Divisione of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland
    Antivir Ther 8:443-54. 2003

Detail Information

Publications40

  1. ncbi request reprint Effect of baseline CD4 cell count on the efficacy and safety of peginterferon Alfa-2a (40KD) plus ribavirin in patients with HIV/hepatitis C virus coinfection
    Milos Opravil
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland
    J Acquir Immune Defic Syndr 47:36-49. 2008
    ..The impact of baseline CD4 status on hepatitis C virus (HCV) treatment response among patients with HIV/HCV coinfection was investigated using data from a randomized study of peginterferon alfa-2a (40KD) + ribavirin (Peg-IFN/RBV)...
  2. doi request reprint CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy
    Nina Khanna
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital, Basel, Switzerland
    Clin Infect Dis 47:1093-101. 2008
    ....
  3. pmc Impact of previous virological treatment failures and adherence on the outcome of antiretroviral therapy in 2007
    Marie Ballif
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
    PLoS ONE 4:e8275. 2009
    ..Combination antiretroviral treatment (cART) has been very successful, especially among selected patients in clinical trials. The aim of this study was to describe outcomes of cART on the population level in a large national cohort...
  4. ncbi request reprint Eligibility for and outcome of hepatitis C treatment of HIV-coinfected individuals in clinical practice: the Swiss HIV cohort study
    Annelies S Zinkernagel
    Division of Infectious Diseases and Hospital Epidemiology, Department of Internal Medicine, University Hospital, Zurich, Switzerland
    Antivir Ther 11:131-42. 2006
    ....
  5. ncbi request reprint Treatment initiation with zidovudine-containing potent antiretroviral therapy impairs CD4 cell count recovery but not clinical efficacy
    Angela C Huttner
    University Hospital of Zurich, Zurich, Switzerland
    AIDS 21:939-46. 2007
    ..We examined the predictive factors for this phenomenon and assessed its impact on clinical progression during treatment in a large patient cohort...
  6. ncbi request reprint Equal amounts of intracellular and virion-enclosed hepatitis C virus RNA are associated with peripheral-blood mononuclear cells in vivo
    Philipp Kaiser
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, 8032 Zurich, Switzerland
    J Infect Dis 194:1713-23. 2006
    ..Quantitation of HCV RNA with regard to its subcellular distribution and longitudinal course is needed for better understanding of the largely unexplored in vivo dynamics and potential pathogenetic significance of HCV in PBMCs...
  7. ncbi request reprint Optimized virus disruption improves detection of HIV-1 p24 in particles and uncovers a p24 reactivity in patients with undetectable HIV-1 RNA under long-term HAART
    Jorg Schupbach
    Swiss National Center for Retroviruses, University of Zurich, Zurich, Switzerland
    J Med Virol 78:1003-10. 2006
    ..It also uncovers the presence of a p24 reactivity, whose identity remains to be determined, in a significant fraction of samples with undetectable HIV-1 RNA under long-term HAART...
  8. ncbi request reprint Attenuated and nonproductive viral transcription in the lymphatic tissue of HIV-1-infected patients receiving potent antiretroviral therapy
    Marek Fischer
    Division of Infectious Diseases and Hospital Epidemiology, Department of Medicine, University Hospital Zurich, Zurich, Switzerland
    J Infect Dis 189:273-85. 2004
    ..Thus, residual lymphoid HIV-1 RNA in patients receiving HAART indicates attenuated viral transcription in HIV-1-infected cells that lack virion production...
  9. doi request reprint Higher CNS penetration-effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid
    Alexia Cusini
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
    J Acquir Immune Defic Syndr 62:28-35. 2013
    ....
  10. ncbi request reprint Impact of genotypic resistance testing on selection of salvage regimen in clinical practice
    Stefan Haupts
    Divisione of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland
    Antivir Ther 8:443-54. 2003
    ..To determine whether genotypic resistance testing leads to selection of more potent drug regimens when compared to regimens based on treatment history only...
  11. ncbi request reprint Effect of individual cognitive behaviour intervention on adherence to antiretroviral therapy: prospective randomized trial
    Rainer Weber
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital, Zurich, Switzerland
    Antivir Ther 9:85-95. 2004
    ..A high level of adherence to antiretroviral therapy is required for complete suppression of HIV replication, immunological and clinical effectiveness. We investigated whether cognitive behaviour therapy can improve medication adherence...
  12. doi request reprint Prior therapy influences the efficacy of lamivudine monotherapy in patients with lamivudine-resistant HIV-1 infection
    Milos Opravil
    Division of Infectious Diseases, University Hospital of Zurich, Zurich, Switzerland
    J Acquir Immune Defic Syndr 54:51-8. 2010
    ..This prospective study aimed to characterize the virologic and immunologic changes during monotherapy with lamivudine (3TC) in patients with limited options for a fully suppressive new therapy...
  13. ncbi request reprint Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy
    Gilbert R Kaufmann
    Division of Infectious Diseases and Hospital Epidemiology, Department of Internal Medicine, University Hospital Basel, Basel, Switzerland
    Clin Infect Dis 41:361-72. 2005
    ..We studied the determinants and the clinical relevance of incomplete CD4 T cell restoration...
  14. ncbi request reprint HIV-specific cellular immune response is inversely correlated with disease progression as defined by decline of CD4+ T cells in relation to HIV RNA load
    Annette Oxenius
    Institute for Microbiology, Eidgenossische Technische Hochschule Zurich, Zurich, Switzerland
    J Infect Dis 189:1199-208. 2004
    ..Slower progression was not related to polymorphisms in CCR genes, HLA genotype, or GB virus C coinfection. These data suggest that HIV-specific T cell responses are involved in protecting the host from disease progression...
  15. doi request reprint Implementation of raltegravir in routine clinical practice: selection criteria for choosing this drug, virologic response rates, and characteristics of failures
    Alexandra U Scherrer
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
    J Acquir Immune Defic Syndr 53:464-71. 2010
    ..Raltegravir (RAL) achieved remarkable virologic suppression rates in randomized-clinical trials, but today efficacy data and factors for treatment failures in a routine clinical care setting are limited...
  16. ncbi request reprint HIV-1 p24 antigen is a significant inverse correlate of CD4 T-cell change in patients with suppressed viremia under long-term antiretroviral therapy
    Jorg Schupbach
    Swiss National Center for Retroviruses, University of Zurich, Zurich, Switzerland
    J Acquir Immune Defic Syndr 33:292-9. 2003
    ..Comparison of p24 antigen and HIV-1 RNA concentrations indicate that the p24 antigen detected in these samples is not associated with viral RNA-containing particles and may originate from other compartments of virus expression...
  17. doi request reprint Natural history of HIV-associated pulmonary arterial hypertension: trends in the HAART era
    Milos Opravil
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland
    AIDS 22:S35-40. 2008
    ..Given recent improvements in the treatment of PAH, the early recognition of these individuals is essential...
  18. ncbi request reprint Pulmonary arterial hypertension related to HIV infection: improved hemodynamics and survival associated with antiretroviral therapy
    Jean Philippe Zuber
    University and Cantonal Hospitals of Zurich, Zurich, Switzerland
    Clin Infect Dis 38:1178-85. 2004
    ..7 years. HAART significantly decreased mortality due to PAHRH as well as other causes. This study suggests a beneficial effect of combination ART in patients with PAHRH...
  19. ncbi request reprint Acute interstitial nephritis of HIV-positive patients under atazanavir and tenofovir therapy in a retrospective analysis of kidney biopsies
    Simone Schmid
    Department of Pathology, Institute of Surgical Pathology, University Hospital Zurich, Schmelzbergstrasse 12, CH 8091 Zurich, Switzerland
    Virchows Arch 450:665-70. 2007
    ..We conclude that acute interstitial nephritis and consecutive acute renal failure is a relevant side effect of atazanavir and tenofovir therapy in HIV-positive patients...
  20. ncbi request reprint Residual cell-associated unspliced HIV-1 RNA in peripheral blood of patients on potent antiretroviral therapy represents intracellular transcripts
    Marek Fischer
    Department of Medicine, University Hospital Zurich, Switzerland
    Antivir Ther 7:91-103. 2002
    ..As shown by limiting dilution analysis, HIV-1 infected cells with such a repressed viral transcription pattern were observed at high frequencies in PBMC from untreated patients...
  21. doi request reprint Phase II study of vicriviroc versus efavirenz (both with zidovudine/lamivudine) in treatment-naive subjects with HIV-1 infection
    Raphael J Landovitz
    Schering Plough Research Institute, Kenilworth, New Jersey, USA
    J Infect Dis 198:1113-22. 2008
    ..We report the results of a phase II dose-finding study of VCV plus dual nucleoside reverse-transcriptase inhibitors (NRTIs) in the treatment-naive HIV-1-infected subjects...
  22. pmc Maraviroc for previously treated patients with R5 HIV-1 infection
    Roy M Gulick
    Weill Cornell Medical College, New York, NY 10065, USA
    N Engl J Med 359:1429-41. 2008
    ..CC chemokine receptor 5 antagonists are a new class of antiretroviral agents...
  23. ncbi request reprint Tenofovir use is associated with a reduction in calculated glomerular filtration rates in the Swiss HIV Cohort Study
    Christoph A Fux
    Division of Infectious Diseases, University Hospital Berne, Berne, Switzerland
    Antivir Ther 12:1165-73. 2007
    ..A growing number of case reports have described tenofovir (TDF)-related proximal renal tubulopathy and impaired calculated glomerular filtration rates (cGFR). We assessed TDF-associated changes in cGFR in a large observational HIV cohort...
  24. doi request reprint Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection
    Gerd Fatkenheuer
    Universitätsklinik Köln, Cologne, Germany
    N Engl J Med 359:1442-55. 2008
    ....
  25. doi request reprint Effect of baseline viral susceptibility on response to darunavir/ritonavir versus control protease inhibitors in treatment-experienced HIV type 1-infected patients: POWER 1 and 2
    Anton Pozniak
    Chelsea and Westminster Hospital, London, UK
    AIDS Res Hum Retroviruses 24:1275-80. 2008
    ..Darunavir/r 600/100 mg twice daily showed efficacy benefits over CPI use regardless of viral susceptibility at baseline, FC to darunavir or boosting type in a population of treatment-experienced HIV-infected patients...
  26. ncbi request reprint Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort Study
    Marcel Wolbers
    Basel Institute for Clinical Epidemiology, University Hospital Basel, Switzerland
    AIDS 21:2201-7. 2007
    ....
  27. ncbi request reprint Combined tipranavir and enfuvirtide use associated with higher plasma tipranavir concentrations but not with increased hepatotoxicity: sub-analysis from RESIST
    Francois Raffi
    University of Nantes, Nantes, France
    AIDS 21:1977-80. 2007
    ..Observed increases in plasma tipranavir concentrations thus had no apparent effect on the risk of hepatotoxicity...
  28. ncbi request reprint A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection
    Milos Opravil
    Division of Infectious Diseases, University Hospital, CH 8091 Zurich, Switzerland
    J Infect Dis 185:1251-60. 2002
    ....
  29. ncbi request reprint Clinical efficacy of early initiation of HAART in patients with asymptomatic HIV infection and CD4 cell count > 350 x 10(6) /l
    Milos Opravil
    Division of Infectious Diseases, University Hospitals of Zurich, Switzerland
    AIDS 16:1371-81. 2002
    ..To evaluate the efficacy of early initiation of highly active antiretroviral therapy (HAART), we compared the clinical course of two nested, matched cohorts within the Swiss HIV Cohort Study...
  30. ncbi request reprint CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study
    Gilbert R Kaufmann
    Basel Center for HIV Research, Division of Infectious Diseases, University Hospital, Basel, Switzerland
    Arch Intern Med 163:2187-95. 2003
    ..Highly active antiretroviral therapy (HAART) for human immunodeficiency virus (HIV)-1 infection allows recovery of CD4 T lymphocytes. Few studies have explored the long-term T-lymphocyte responses to HAART...
  31. ncbi request reprint Meta-analysis of randomized controlled trials of simplified versus continued protease inhibitor-based antiretroviral therapy in HIV-1-infected patients
    Heiner C Bucher
    Basel Institute for Clinical Epidemiology, University Hospital Basel, Kantonsspital Basel, Switzerland
    AIDS 17:2451-9. 2003
    ..To evaluate the efficacy and safety of simplified maintenance therapy (SMT) compared with continued protease inhibitor (PI) therapy...
  32. ncbi request reprint HIV replication elicits little cytopathic effects in vivo: analysis of surrogate markers for virus production, cytotoxic T cell response and infected cell death
    Georg A Funk
    Ecology and Evolution, Clausiusstrasse, ETH Zurich Zentrum, Zurich
    J Med Virol 78:1141-6. 2006
    ..25) cytopathic effect (P < 0.05, N = 36). It is concluded that HIV replication elicits little cytopathic effect in productively infected cells and that CD4(+) T lymphocytes are eroded by other mechanisms...
  33. ncbi request reprint Persistence of lamivudine-sensitive HIV-1 quasispecies in the presence of lamivudine in vitro and in vivo
    Kristina Allers
    Institute of Clinical and Moleculr Virology, University of Erlangen Nuremburg, Erlangen, Germany
    J Acquir Immune Defic Syndr 44:377-85. 2007
    ....
  34. ncbi request reprint Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study
    Jacques Fellay
    Division of Infectious Diseases, University Hospital of Lausanne, Lausanne, Switzerland
    Lancet 359:30-6. 2002
    ..This variability could have a genetic basis. We did a pharmacogenetics study to analyse the association between response to antiretroviral treatment and allelic variants of several genes...
  35. ncbi request reprint Long-term safety of discontinuation of secondary prophylaxis against Pneumocystis pneumonia: prospective multicentre study
    Claudine Zellweger
    Division of Infectious Diseases, University Hospital of Berne, Berne, Switzerland
    AIDS 18:2047-53. 2004
    ..To assess the long-term safety of discontinuation of secondary anti-Pneumocystis prophylaxis in HIV-infected adults treated with antiretroviral combination therapy and who have a sustained increase in CD4 cell counts...
  36. ncbi request reprint Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension
    Olivier Sitbon
    Hopital Antoine Beclere, 157 rue de la Porte de Trivaux, 92140 Clamart, France
    Am J Respir Crit Care Med 170:1212-7. 2004
    ....
  37. ncbi request reprint Long-term efficacy after switch from protease inhibitor-containing highly active antiretroviral therapy to abacavir, lamivudine, and zidovudine
    Milos Opravil
    AIDS 18:2213-5. 2004
  38. ncbi request reprint Abnormalities of body fat distribution in HIV-infected persons treated with antiretroviral drugs: The Swiss HIV Cohort Study
    Enos Bernasconi
    Hospital of Lugano, Lausanne, Switzerland
    J Acquir Immune Defic Syndr 31:50-5. 2002
    ..1 [95% CI, 0.6-1.8]; 6-24 months, OR = 2.4 [95% CI, 1.7-3.5]; and >24 months, OR = 3.2 [95% CI, 2.4-4.3]). This study confirms the association between the use of stavudine and lipodystrophy...
  39. ncbi request reprint Adverse events to antiretrovirals in the Swiss HIV Cohort Study: effect on mortality and treatment modification
    Olivia Keiser
    Institute of Social and Preventive Medicine ISPM, University of Bern, Switzerland
    Antivir Ther 12:1157-64. 2007
    ..Antiretroviral therapy (ART) decreases morbidity and mortality in HIV-infected patients but is associated with considerable adverse events (AEs)...
  40. ncbi request reprint Impact of occasional short interruptions of HAART on the progression of HIV infection: results from a cohort study
    Patrick Taffe
    Coordination and Data Center, Swiss HIV Cohort Study, Lausanne University Hospital, Lausanne, Switzerland
    AIDS 16:747-55. 2002
    ..Data from the prospective Swiss HIV Cohort Study were used...